Nubeqa is one of just a few new drugs that Bayer can count on for growth, and the androgen receptor inhibitor has just delivered again with a Phase III success in prostate cancer.
Bayer’s Nubeqa Study Success Will Broaden Its Prostate Cancer Reach
The Phase III study success is good news, but not the surprise upside that Bayer needs to lift investor sentiment.
More from Clinical Trials
More from R&D
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.